Why Attend?

Agenda
CLE

What’s the Buzz? Cannabis-derived products are at a dynamic legal and regulatory crossroads at both the state and federal level. While cannabis-derived substances above 0.3% THC are still illegal at the federal level, states are continuing to legalize cannabis for medical and/or recreational use; many states even designated cannabis businesses as “essential” during the initial phases of the COVID-19 pandemic. Simultaneously, CBD products, many with unsubstantiated drug claims or containing toxic substances, continue to proliferate despite scant FDA oversight. This conference will examine the present reality of this unique industry from both a legal and practical perspective and guide attendees on how to navigate this constantly changing legal environment. Industry experts will untangle the issues related to CBD, cannabis, and other cannabinoids, various regulated product areas (e.g., topicals, supplements, edibles, drugs), and state vs. federal regulation.

Conference Highlights:

  • The current federal regulatory landscape for CBD-derived products
  • CBD safety, product quality, labeling, and marketing considerations
  • CBD litigation and enforcement trends
  • Updates on the Agriculture Improvement Act of 2018 implementation
  • Cannabis state legalization developments
  • Cannabis research initiatives and regulatory updates

Register

 

Industry & Firms

$799
  • +$200 for non-members

Non-Profit

$599
  • +$100 for non-members

Government

$599
  • +$100 for non-members

Academic

$599
  • +$100 for non-members

Student

Free

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.

You can transfer your registration to another person at your organization for no cost by notifying us of the change. If you notify FDLI in writing at least five business days prior to the meeting, you can cancel your registration for a full refund (less a $75 fee). Refunds will be applied against the original form of payment.  

Our event policies are listed here. If you should have any further questions, please contact us at [email protected] or 800-956-6293.

Sponsors

Sponsorship opportunities are available. Please let us know if you would like more information.

Gold Sponsor

 

Gold Sponsor

Gold Sponsor

Gold Sponsor

Silver Sponsor

Silver Sponsor

 

Silver Sponsor

Call for Proposals 

FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this summer. The input received from industry stakeholders helps us plan a timely program. If you submitted a proposal, you will be notified of the status of your proposal in September.

Planning Committee

Karen Balderama, Wendel Rosen LLP
Tina Beamon, Karyopharm Therapeutics
Rodney Butt, Nutrasource Pharmaceutical & Nutraceutical Services
Katherine Ciambrone, Phillip Morris International
Tara Lin Couch, EAS Consulting Group
Delia Ann Deschaine, Epstein Becker & Green, PC
Samantha Dietle, Hogan Lovells US LLP
William Garvin, Buchanan Ingersoll & Rooney PC
Kate Hardey, McGuireWoods LLP
Jonathan A. Havens, Saul Ewing Arnstein & Lehr LLP
Keith Matthews, Wiley LLP
Daniel McGee
Deborah Miran, DMiran Consulting
Heike Newman, University of Colorado
Daniel Charles Rubenstein, Steptoe & Johnson LLP
Juan Luis Serrano-Leets, Sánchez Devanny
Howard R. Sklamberg, Arnold & Porter LLP
Frederick A. Stearns, Keller and Heckman LLP
Justin M. L. Stern, Duane Morris LLP
Thomas Tobin, Perkins Coie LLP